Myth or Not?
For Novartis’s Myth or Not campaign, developed videos, digital marketing and print assets for KESIMPTA® (ofatumumab), a self-administered, monthly subcutaneous injection for adults with relapsing forms of multiple sclerosis (MS).
The HCP-facing campaign showcases conversations between medical experts who discuss real-world adherence data and administration of KESIMPTA, while addressing common myths and misconceptions.
NEDA-3 may only be useful in the clinical trial setting
Barry Hendin, MD and Sharon Stoll, MD discuss KESIMPTA® (ofatumumab) and the practicality of NEDA-3 in practice outside of the trial setting
Myth or Not?
Real-world adherence results for a self-administered B-cell therapy: Can it help guide at-home treatment discussions?
Myth or Not?
Can high-efficacy therapy also have a demonstrated safety and tolerability profile?
